IRVINE, Calif., and SEATTLE, Nov. 26 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) and Cell Therapeutics, Inc. (Nasdaq: CTIC)(MTA: CTIC) announced today they have entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, to commercialize and develop ZEVALIN(R) ([90Y]-ibritumomab tiuxetan) in the United States. ZEVALIN, a radioimmunotherapeutic (RIT), is currently marketed in the United States by Cell Therapeutics, Inc. (CTI) for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. CTI submitted a supplemental Biologics License Application (sBLA) in September 2008 to expand the label for use in first-line consolidation therapy in previously untreated patients with follicular NHL.
Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with, and approximately 19,160 are expected to die from, this disease in 2008. According to the National Cancer Institute's SEER database, there were approximately 400,000 people in the U.S. with NHL in 2004.
"ZEVALIN represents a powerful addition to our marketed oncology drug
portfolio," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer,
and President of Spectrum Pharmaceuticals. "ZEVALIN is safe and ef
|SOURCE Spectrum Pharmaceuticals, Inc.; Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved